Page 8 - Lifesci Advisors News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024

NEW YORK, May 27, 2024 Cellectis , a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will.

New yorkUnited statesFrance generalNorth carolinaPascalyne wilsonAshleyr robinsonArthur strilPatricia sosa navarroCellectis the company euronext growthEuronext growthNasdaq global marketSosa navarroInterim chief financial officerLifesci advisors

Enterome Highlights High Complete Response Rate in Clinical Study of EO2463 for Indolent Non-Hodgkin Lymphoma at ASCO 2024

Enterome Highlights High Complete Response Rate in Clinical Study of EO2463 for Indolent Non-Hodgkin Lymphoma at ASCO 2024
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

France generalUnited statesAshleyr robinsonJan fagerbergGuillaume bayreWeid europeLifesci advisorsHead of external communicationsHealth scienceDivision of hematologyAmerican society of clinical oncologyHighlights high complete response rateClinical studyIndolent non hodgkin lymphomaAmerican societyClinical oncology

Theriva™ Biologics Announces Fast Track Designation Granted by the U S FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer

Theriva™ Biologics Announces Fast Track Designation Granted by the U S FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesTheriva biologicsChris calabreseStevena shallcrossBiologics incTheriva biologics incLifesci advisorsCompany annual report on formDrug administrationMetastatic pancreaticFast track designationChief executive officerTheriva biologicPrivate securities litigation reform actAnnual reportSci advisors

Theriva Biologics, Inc : Theriva Biologics Announces Fast Track Designation Granted by the U S FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer

ROCKVILLE, Md., May 23, 2024 (GLOBE NEWSWIRE) Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in

United statesStevena shallcrossChris calabreseTheriva biologicsTheriva biologics incDrug administrationCompany annual report on formLifesci advisorsFast track designationChief executive officerTheriva biologicPrivate securities litigation reform actAnnual reportSci advisorsIhr portfolio

Theriva™ Biologics Announces Fast Track Designation Granted

Theriva™ Biologics Announces Fast Track Designation Granted
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

United statesChris calabreseStevena shallcrossTheriva biologicsLifesci advisorsCompany annual report on formDrug administrationTheriva biologics incBiologics incFast track designationChief executive officerTheriva biologicPrivate securities litigation reform actAnnual reportSci advisors